Novartis AG
LIQUID IL-1 BETA ANTIBODY FORMULATION HAVING PH OF 5.5 TO 7.0
Last updated:
Abstract:
The present invention relates to novel pharmaceutical formulations, in particular novel pharmaceutical formulations in which the active ingredient comprises human antibodies to human interleukin I beta (IL-1.beta.), in particular ACZ885 antibody, pharmaceutical formulations which are stable and aggregate-free upon storage and delivery.
Status:
Application
Type:
Utility
Filling date:
16 Jul 2020
Issue date:
10 Dec 2020